Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias
A significant fraction of chronic myeloid leukemia (CML) patients relapse from first-generation (1G) tyrosine kinase inhibitor (TKI) therapy, and this could be prevented by the de novo use of 2G TKIs. However, there are no patient stratification markers to guide clinicians in the selection of frontline TKI therapy for optimal outcomes in CML patients. Here, identical results from two independent CML cohorts indicate that the determination of NOCIVA mRNA levels by clinically approved qPCR platforms from de novo chronic phase CML patients could provide significant support for clinicians in recognizing patients in need of first-line 2G TKI therapy. In acute myeloid leukemia (AML), high NOCIVA/CIP2A ratio at diagnosis could indicate a need for first-line therapy intensification.
Recent Posts
- Turku Metabolomics Core Enhances MALDI Imaging with New Sprayer The Turku Metabolomics Core, part of the Turku Bioscience Centre, has acquired a SunCollect MALDI Read moreSeptember 19, 2025
- Christel Sourander Successfully Defends Her Thesis Congratulations! Christel Sourander successfully defended her thesis: “Identifying the effect of JNK on neural activity Read moreSeptember 9, 2025
- Researchers at Åbo Akademi University Discover a New Molecular Switch Regulating Breast Cancer Progression A research group led by our our affiliated group leader Professor Lea Sistonen at Åbo Read moreSeptember 4, 2025
- Autumn 2025 Frontiers of Science seminars start soon Frontiers of Science is a long-running seminar series, celebrating over 25 years of bringing internationally Read moreSeptember 3, 2025
- The Elias Tillandz Prize to Turku Bioscience Researchers The Elias Tillandz Prize for the Best Scientific Publication of 2024 was presented for two Read moreSeptember 2, 2025
- Registration to FFGC Sequencing day is open! Registration to FFGC Sequencing day is open! The event is organized by Finnish Functional Genomics Read moreAugust 27, 2025